Q3 2021 Turning Point Therapeutics Inc Earnings Call
[music].
Good day and thank you for standing by welcome did up there any point therapeutics third quarter 2021 conference call.
At this time all participants are in a listen only mode. After the speaker presentation, there will be a question and answer session.
A question during the session you will need to press star one on your telephone if you require any further assistance. Please press star zero I would now like to hand, the conference over to your speaker today, Adam Lindsey. Thank you. Please go ahead.
Thank you operator, good afternoon, everyone first let me start by saying I'm happy to be on the call today and to be joining the turning point team at such an exciting time for the company.
I also wanted to thank Scott Lipman from managing our Investor Relations activities recently, and I look forward to working with many of you going forward.
Following market close today, we filed our Form 10-Q and issued a news release with a summary of our results for the third quarter of 2021.
We also updated our investor presentation, you may find these documents posted on the investor's pages of TP Therapeutics Dot com.
Leading the call today, we will be turning point's, President and Chief Executive Officer, Dr. Athena country, Otis, who will provide an overview and update on our business results before turning the call over to Paulo, <unk>, Our Chief Financial Officer for a review of our financials.
We will take questions. Following our prepared remarks, and we will be joined by Dr. Mohammad <unk>, Our Chief Medical Officer.
Before <unk> begins I want to remind you that during this conference call, we will be making forward looking statements. The company's actual results may differ materially from those expressed in or indicated by such forward looking statements for.
For a description of risk factors associated with investing in turning point therapeutics.
Refer to our recent filings with the Securities and Exchange Commission now, let me turn the call over to Athena.
Thank you Adam and good afternoon to everyone joining us on today's call.
As this is our last quarterly call in 2021, I want to start by highlighting what I believe to be the true strength of our turning point team and the <unk>.
Past three years, we have advanced our macrocyclic platform from one phase one clinical stage asset in one ongoing clinical trial to now four clinical stage assets in six ongoing clinical trials.
In addition, we have received a total of nine regulatory designations for our pipeline, including two breakthrough therapy designation for our lead asset re Protract nib.
Our company has scaled rapidly from 2018, when we were fewer than 20 employees to now over 230 employees with a clear focus on continued innovation with research and discovery as well as expertise in clinical development and regulatory.
With that background in our current $1 billion in cash we believe we are well positioned to advance our pipeline and are looking to the future as you prepare for a potential launch of <unk> with additional growth in our medical affairs and commercial teams.
Our current macrocyclic platform was internally developed to design highly potent small and compact inhibitors that could potentially differentiate by overcoming treatment resistance or increased durability of response in indications where few therapeutic advancements have been made.
Since then multiple recent launches in the Ross one track, Matt and Alex spaces have occurred.
Yes, we continue to believe in the potential differentiation of our pipeline.
Focusing on <unk>, we believe it could be a potential best in class Ross one inhibitor based on the data. We previously reported in the Ross one positive <unk> naive and Teekay pretreated non small cell lung cancer.
In addition, we are encouraged by the early signals seen in <unk> positive advanced solid tumor patients and the recent breakthrough therapy designation granted in the TK pretreated patient population, where there are no currently approved targeted therapies.
Moving to our second drug candidate, we believe in the potential of <unk> to show differentiation as it continues and development, especially due to the biologic rationale supporting the co targeting of CSF, one or an <unk>.
Has the potential to prolonged duration of response.
We are focused on finalizing our recommended phase two dose and studying <unk> in a less heavily pretreated patient population, where we can further evaluate its potential.
Rounding out the pipeline our two additional drug candidates PBX 0046, and <unk> one.
And phase one dose finding studies.
We look forward to sharing our planned milestones for these programs in the first quarter of next year, along with updates from multiple upcoming interactions with the FDA for both <unk> and <unk>.
Shifting now to recent highlights since our last quarterly call.
I'm, especially pleased with the progress our dedicated and talented turning point team made as you received two regulatory designations from the FDA for we subtract nib.
<unk> the Trident two combination study of <unk> and K Ras mutant <unk> solid tumors, our sixth clinical study presented for data updates across our pipeline and announced the clinical collaboration with EQ Rx.
In addition, we continue to strengthen our executive team. Most recently with the hiring of Adam who joined US yesterday as senior Vice President of Investor Relations and corporate Communications I am pleased to introduce Adam and welcome him to our team.
He brings more than 20 years of experience across both large and small biopharmaceutical companies and I look forward to many of you working closely with Adam overtime.
Today, I will recap our recent accomplishments and provide more details on our anticipated future regulatory milestones into 2022.
Overall, we continue to advance our four clinical stage next generation tyrosine kinase inhibitors that target genetic drivers of cancer and our ongoing discovery work, where our goal is to nominate two development candidates in the second half of 2022.
One targeting <unk> <unk> and the other targeting path, both known to play a large roles in a barren GTP signaling.
We specifically chose these targets due to the strong biologic rationale and potential market opportunities given the addressable patient populations and the limited number of competitive targeted agents that are approved and encourage clinical development.
I will begin with our lead program <unk> or Ross one track inhibitor. We've been tracking it is currently being studied in our ongoing multi cohort registrational Trident one study in patients with Ross one positive advanced non small cell lung cancer and <unk> positive advanced solid tumors. We received our second breakthrough therapy designation granted by the FDA.
For <unk> in early October.
<unk> was granted for the treatment of patients with advanced solid tumors that haven't and Trek gene fusion, who have progressed following treatment with one or two prior truck <unk> with or without prior chemotherapy and have no satisfactory alternative treatments.
As a result, we plan on discussing next steps towards registration of <unk> in patients with <unk> positive T. J pretreated advanced solid tumors at a type B meeting with the FDA next month.
We now receive <unk> for both <unk> and <unk> patient populations, we are well positioned to continue to have frequent dialogue with the FDA regarding our registration strategy in.
In October we presented three clinical data updates for <unk> two from the Registrational Trident, one study and one from the phase <unk> study in pediatric and young adult patients.
Overall, <unk> continued to demonstrate promising clinical activity, including in the TK Pretreated Ross one positive non small cell lung cancer and <unk> positive advanced solid tumor settings.
There are currently no approved targeted therapies.
Looking into 2022, we plan to discuss the blinded independent Central review data from all four of the Ross one positive non small cell lung cancer cohorts of Trident, one with the FDA at a pre NDA meeting anticipated in the second quarter of 2022.
At this meeting we plan to discuss available <unk> ICR data in at least 50, <unk> naive and 50 Teekay pretreated patients with at least six months of follow up for the majority of responders.
We plan to report the top line the ICR data from these cohorts in the second quarter of 2022.
Now, let me shift to some of the advancements we have made as we prepare to be a commercial organization.
Since hiring our chief commercial officer, Andy last July we've continued to build out our commercial leadership team.
This team is continuing engagement with Kols and high volume prescribers and community and academic settings in.
In addition, our medical affairs team continues to grow and is engaging thought leaders both in the U S and globally.
Based on our interactions with oncologists, we have continued to refine our understanding of the opportunity for <unk>.
The feedback we have received has been consistent across market research advisory boards and one on one interactions which is that compared to the two approved therapies. A higher response rate increased durability increased progression free survival and or the ability to treat or potentially delay the emergence of resistant mutations could be clinically.
Paul in the Ross, one positive teekay naive non small cell lung cancer setting.
As a reminder, we've previously reported a higher response rate than historically reported with our competitors in the Ross one positive teekay naive setting from our preliminary phase II datasets.
As well as a median duration of response of 23, one months in median progression free survival of $24. Six months 11 patients previously reported from the phase one portion of the Trident One study utilizing a blinded independent Central review analysis.
In the Ross one positive Teekay pretreated setting there are limited options for patients outside of cytotoxic chemotherapy or <unk>, which is not approved in this setting and has not demonstrated confirmed responses in patients with the <unk> 200, <unk> solvent front mutation.
In addition, our interactions with oncologists have highlighted that the ability to overcome resistant mutations would be clinically meaningful in this setting.
As we look at the opportunity in <unk> positive advanced solid tumor patients. We are encouraged by our preliminary data in this patient population.
Based on our data we believe in <unk> best in class potential in the TGI pretreated setting, where we recently received breakthrough therapy designation and there are no currently approved targeted therapies.
Overall based on our research and data for <unk>, we continue to be excited about its potential in both the Ross one and <unk> settings.
Next in our pipeline as well as advanced <unk> or <unk> are met stark in CSF Oner inhibitor currently being studied in our ongoing phase one shield one study in patients with advanced solid tumors harboring genetic alterations in met.
At the ACR NCI <unk> meeting we were encouraged by the updated preliminary data for <unk> that was reported from the phase one dose finding portion of the study.
There are no currently approved targeted therapies and net amplified non small cell lung cancer or gastric cancer and we believe we have multiple opportunities to differentiate <unk>, including in the exon 14, skipping non small cell lung cancer indication and in both met amplified non small cell lung cancer and gastric cancer in.
Third quarter, we completed an end of phase one meeting with the FDA focused on next steps for <unk> in non small cell lung cancer during.
During the meeting we received guidance on the design of the planned phase III portion of shield, one and feedback on our recommended phase II dose. We proposed a recommended phase two dose of 40 milligrams daily to 40 milligrams twice daily based on the available data at the time of the meeting.
The FDA recommended that we explore an additional intermediate dose level using the QD titration to be IV dosing strategy and at least six to 10 patients prior to starting the phase II portion of the study.
Patient screening at the intermediate dose level of 60 milligrams daily to 60 milligrams twice daily is ongoing and we plan to enroll at least six to 10 patients at this dose as quickly as possible.
We plan to provide data from this dosing cohort to the FDA when available with the intention of revising the shield one study entry potentially registrational phase <unk> design and initiating the phase II portion in 2022.
While we focused on enrolling the intermediate dose level. We are also continuing to enroll patients in the phase one dose expansion portion of the study at the 40 milligram daily to 40 milligram twice daily titration dose level.
In addition, we anticipate feedback on the development path for <unk> for the treatment of met amplified gastric cancer next month.
Lastly, as it relates to <unk>, we were excited to announce a clinical collaboration with <unk> to evaluate <unk> in combination with <unk> <unk> Egfr inhibitor in patients with Egfr mutant met amplified advanced non small cell lung cancer.
We are planning to initiate the shield two combination study in mid 2022 pending clearance of the IND by the FDA in the first half of next year.
Rounding out our pipeline, our TPS 0046, our ret inhibitor and <unk> hundred one our CNS penetrant <unk>. We are currently enrolling patients in the phase one dose finding portion of the sword. One study for <unk> six and the phase one dose finding portion of the forge one study of <unk> hundred one.
Lastly, turning to discovery, we have four internal programs that target a barren GTA signaling known to drive genomics defined cancers with significant unmet medical need.
Our most advanced programs focus on <unk> and pack, where we are targeting two development candidates in the second half of 2022.
Our goal is to submit one IND per year beginning in 2023.
We believe these are potentially meaningful opportunities given the limited number of targeted agents that are approved and in clinical development in these indications.
Now, let me turn the call over to Paulo to provide an update on our financial results.
Thank you and welcome to everyone on the call.
In our press release and financial tables that operating expenses for the third quarter totaled $67 $1 million compared to $43 5 million in the third quarter of 2020 research and development expenses were $48 $9 million in the quarter compared to $32 2 million last year.
The $16 $7 million increase with Brian whether you did or even by the year over year increase in investment to develop <unk> as Dubai.
Anthony Dps Vod cohort seeks dps zero, one for one and discovery efforts and personnel expenses general and administrative expenses were $18 $2 million compared to $11 3 million in the third quarter of 2020. This increase was primarily due to higher personnel expenses growing increasingly count in <unk>.
First one on fees, including those associated with launch readiness.
We expect expenses to continue to ramp as our clinical and discovery programs progress and as we make additional investments to prepare for the potential launch of <unk> protection.
Net cash used during the first nine months of 2021 totaled $86 $5 million cash cash equivalence and marketable securities at September 30 totaled approximately $1 billion. We continue to project our cash position fund current operations into 2024 now let me turn the call back.
Got you.
Thank you Paolo.
To close I will summarize the expected timing of our anticipated regulatory interactions and the associated milestones for <unk> and <unk>.
First for <unk>, we look forward to our planned type B meeting next month with the FDA to discuss next steps towards registration of <unk> in patients with <unk> positive T. J pretreated advanced solid tumors.
In addition, we anticipate reporting topline blinded independent Central review data from all of the Ross one positive non small cell lung cancer cohorts from tried it Juan and discussing the ICR data with the FDA at a pre NDA meeting in the second quarter of 2022.
Next trials <unk>, we anticipate FDA feedback on the development path and met amplified gastric cancer next month, we also anticipate initiating the shield two combination study of <unk> with <unk> <unk> Egfr inhibitor in mid 2022 pending clearance of the IND by the FDA in the first half of next year.
Lastly, we look forward to continuing progress across our pipeline and discovery work and to outlining plans for our program updates next year.
With that we are now ready to take your questions. Operator, you may now open the line for questions.
Certainly as a reminder to ask a question you will need to press star one on your telephone again to ask a question. Please press Star then the number one on your telephone keypad.
Your question. Please press the pound key.
By while we compile the Q&A roster.
Our first question comes from the line of Paul Choi from Goldman Sachs. Your line is now open.
Thank you everyone. Good afternoon nice to hear all your voices and I welcome to Adam and thanks for taking our questions.
A couple for us.
And then maybe starting with <unk> can you maybe just first update us on how quickly you think you'll be able to.
And roll those six to 10 additional patients for the 40 Meg dose titration plan and then secondly, continuing analysis of assets do you expect to be able to present additional data from the <unk>.
Phase one expansion portion of the.
Of the shield one study in <unk>.
In the front half of next year, then I had a follow up question.
Hi, Paul Thank you for the questions. So first let me just start by saying that the phase one enrollment from 60 make 60 make which is the intermediate dose level has started screening patients and we look forward to enrolling as quickly as we can I can give you more in terms of when we will have that number of 6% to 10 patients, but I am.
Encouraged with what I've seen so far from conversations with Mohamad I think equally what mom is done which is very smart with our team is to continue to enroll in the less heavily pretreated patients in dose expansion of the phase one or alternative which is 40 milligrams to 40 milligrams PID. So I do think we'll have a robust data set to show to the FDA now that said I can't predict whether we will have data.
To show publicly prior to that FDA meeting, but will be in a better position to guide to that once we've completed enrollment.
Okay. Thanks, Athena then maybe as a follow up I think one of the investor questions posted Triple meeting was just thinking about the response rates in the lung patients and I wanted to just ask you how you're thinking about perhaps.
Expansion into the lung patient population I'm, just thinking about like the Exxon 2014.
Patients in particular, and just maybe exploring that more in depth to get greater clarity on the potential signal there.
Yes, happy to I mean I think.
One of the things coming out of the Triple meeting as one we were encouraged by the data remembering that this is still a phase one dose finding updates.
That said again it was an all comers still heavily pretreated, we had one patient who had responded out of the five but this is a patient that's been treated at MD Anderson now almost two years and I was pleased when Dr. Hung on the call mentioned that comment because again one of the strengths I believe and this drug is its ability to increase durability of response.
Now that said if you looked at the total five number of patients that we had in that population three we had three or higher prior lines of therapy. So again, it's not truly an apples to apples and yet I. Appreciate everyone is comparing a 20% response rate essentially to what is in an approved label post one chemotherapy, which is post platinum with <unk>.
Let's say a mid 40% response rate I do not think that is the appropriate comp.
He said that I do think comparing to a phase one dataset is the right comp and remembering that cat matinee treated approximately 40 patients.
All comers and had no responses. So when we look forward to the next steps again of course, the focus here is to get through the intermediate dose level as quickly as we can but we really look forward to studying this drug in a less heavily pretreated population, which Mohammad is already doing in the 40 million to 40 make the IV cohort now in dose expansion.
Okay. Thanks, I'll jump back in queue.
Okay. Thanks, Paul.
Our next question comes from the line of Michael Schmidt of Guggenheim. Your line is now open.
Hey, Thanks for taking my questions Athena I had two the first one is on track to Nab.
To clarify again with us.
Regarding the upcoming FDA meeting in the second quarter of next year.
What are the key points are that debt.
We plan to discussing that and what potential outcomes could be and then I had a follow up.
Yes sure.
One of the things we wanted to highlight today is that our intention is to have the FDA meeting in the second quarter and to provide the data in the second quarter I do believe that some thoughts after the triple meeting update that the data may not come until later and so we wanted to clarify that today. So our current plan is to bring the topline blinded independent Central review.
Data of which we've not done that analysis at least 50 patients who are naive and 50 patients who are teekay pretreated and Thats based on the most recent updates we just showed in the TK pretreated populations with at least six months of follow up for the majority of responders in Q2, that's our base plan, we would normally provide the data after <unk>.
Formal minutes, but we are evaluating currently whether we could do that differently and whether we could submit it especially the topline data to a medical conference and so we'll be in a better position to provide more details there as we approach the timeline of the event next year now as it relates to the outcomes of the meeting as we've always said the key in my opinion is whether the FDA agrees with based on.
The totality of the data set whether six months of follow up will be submission sufficient given this is a pre NDA meeting to support an NDA timeline and Thats really the key question that comes out of that meeting whether it will be six months or it will be reverted to our original base case, which was 12 months and just reminding that Roswell Trek has to come in with 12 months of follow up for.
All responders. So we are trying to beat that based on the fact that we received breakthrough therapy designation and they did not.
Got it and then just a question on losses.
I think we've talked about this before the fact that the the full data which was <unk>.
Generated later had a lower response rate than what's reflected in the FDA label.
And Ross one patients and then I was just wondering if you had any additional insights as to potential updates to your competitive threats.
At some point.
One of the things I think again as I highlighted in my prepared remarks I do believe this company differentiates on is the strength within our clinical development and regulatory teams and of course, that's led by Muhammad we were watching very closely not only the approval of Roswell Roswell track, but as I've said for many months for individuals to look at actually the approval letter not just the pack.
And Sir because the approval letter showed that there was commitments to bring more data and then of course, we saw that data updated last year at ESMO, where to the point Youre, making the Rosa track response rates became essentially the same as <unk> at 67% the duration of response of $15 seven months and the progression free survival of $15.
Seven months, which is inferior to <unk> or do you think that is one of the reasons that this drug has performed poorly in the marketplace now whether the FDA will take all of that data. We know the FDA won't put in progression free survival into most single arm studies into a package insert but would you anticipate at some point. The response rate will be updated based on that was a request from them.
Just can't predict when the timing of that will occur.
Okay. Thanks for the.
<unk>.
Our next question comes from the line of Matt Biegler with Oppenheimer. Your line is now open.
Oh, Hey, guys. Thanks for the question.
Just alluded to this in your last remark, but I.
Okay, and I do think it's to some extent those numbers I just gave him I think people are misquoting thinking that razo trucks progression free survival is better than all Cory it's actually worse and so what is the place for that drug and again I think that we have a differentiated asset I think that that has been shown based on our breakthrough therapy designation that they did not receive and the consistent updates that we've shown now remember.
During that at this point, we've yet to do are blinded independents interview analysis, but but really nothing has changed in my mind irrespective of that drugs lunch.
Got it alright, so maybe just a quick follow up on this upcoming type B. This quarter. This is new right and I don't want to read too much into it but.
Do you think it might be possible, depending on what the FDA once per bullet from west Roswell on that and and check filing could actually come before.
One or are you still thinking of combining them together or do you think Ross one ruled on before it kind of what's your thoughts Sir thanks.
Yeah, I mean first of all as you can appreciate I Wanna get re protraction of on the market as quickly as I can and I think again, that's one of the strengths of this team is that we've been pursuing every avenue and so again, our second breakthrough therapy designation enabled the second type be meeting. This meeting will be very similar I hope in the intensive the Ross one meeting that we performed earlier this year, which is to get more regular.
Tori guidance now previously they've already given that six months of follow up was sufficient as long as we provided a heterogeneous number of tumor types and so this meeting allows us to have more conversations with them show us show them excuse me the robustness not only of the tumor types, but also of the different fusion partners that we have within.
Our data set and then really discuss how many patients would be required now remembering again, we've not yet done the blinded independent Central review analysis here, but of course, we have breakthrough therapy designation. So I can't predict that this would be the first NDA, but if we're going to pursue as quickly as we can based on the feedback coming out of this meeting.
Got it thanks for the question.
Thank you Matt.
There are no further questions coming in at this time I am now turning the call back to Athena contact you out there.
Oh, well, thank you very and follow up questions at Dinah would you like to take them. Okay sure of course.
Next question comes from the line of Zed bed Zola after raft capital partners. Your line is now open.
Hi, Thanks for taking my question and apologies for the delay I just have three quick wins Athena. The first one is just about if possibly pediatric data relative to the adult data that was presented and it sounds like you're going to be separating the that as opposed to lock the weather combine the pediatric and adult and so.
Just wanted to have you had any comments about that.
Thank you for the comments.
So I trained in pediatrics, so I'm incredibly encouraged by being able to treat pediatric patients. The pediatric program of course, we had the oral presentation at by up showed in my belief again in a very small patient population activity not only just and trek chica naive patients of which we had a very young child with a glioblastoma who has remained.
And a complete response after multiple rounds of prior chemotherapy and again as a physician I find that incredibly encouraging but as it relates to the future for reap attractive in the NDA, we've not yet committed to dividing the dataset and in fact, that's something that we'll discuss when we bring the data to the FDA not only just sit tight be an effort obviously in the future.
Perfect. Thanks for the clarification, and then I'm glad to hear that you've been doing until market research as it relates to protect anyone I was just wondering can you comment a little bit more on who exactly with sample done then are there any updates on perhaps a brighten up the market size or any new updates on.
Increase in patient identification, just because you're more therapies now improved.
Yeah, well, let me just start with what I tried to say in the prepared remarks also since the hiring of Andy I mean, one of the things I think Andy has really done an amazing job is bringing in a very talented team. We've just brought in our head of customer engagements. We previously have already brought in our head in terms of payer reimbursement as well as marketing and so we're trying to fill.
All the teams now as we prepare for a potential launch our initial market research campaign was quite broad it was not only the U S. It was also Europe and Japan, because each of those markets I think are very applicable to our future I can't give any more in terms of changes as it relates to the market size, our patients identification, but I really do look forward to introducing Andy to you and to everyone on.
Call in the future.
Things at the end and then the last one year's just about elder Vance Nib I know you said that you may or may not present.
Data from the expansion, but I was just wondering how much are you going to be looking at that data to drive some of your decision, making not only for the dose but in terms of efficacy enemies early my patients.
Yeah, I mean first of all let me clarify I hope I didn't say that we wouldn't presented I just don't have private information at this time to say when the intention would be to be looking predominantly at the pharmacokinetics as well as the safety and of course, if there's any encouraging signals of activity to provide to the F. D. A I do think again, one of the things that Mohammed and the.
[noise] team really did a great job that is negotiating with the F. D. A that we will provide this information through and invest informational amendment and receive feedback within 30 days. So we will not need a new type C meeting with the F. D. A to hopefully advance into phase two so that potentially can speed up our timeline and then I'll have better clarity as to what if we're going to do this in a medical conference.
Et cetera, when we get closer to 2022.
Things and come back and help with Comcast.
Thank you very much bye bye.
Our next question comes from the line of Andrew Barons of S. V. B link your line is now open.
[noise]. Thanks, I appreciate your fever, sorry, if I missed some of those I'll spell turnaround between a few things going on simultaneously.
Could I just clarify when we will see more of a teacher night cohort.
From the phrase to reboot trial I know you said you would discuss the data into 222 clubs is there a chance we might see an update like last year around J P. Morgan and then I have a question on the matter you answer that.
Yeah sure. Thanks, Andy I'm in currently our our focus is getting the binding independent Center review data and so at this point, what we're saying is we plan on providing the data in queue too that would include not only the TK naive data as well as the Teacake retreated all by blinded independent Central review.
Okay.
And then.
On the program.
40 milligram dose.
Does the Fda's request, driven primarily by I need to see the efficacy of that level or was it a safety tolerability can sir.
That was just wanted also no remark through some of the early al Qaeda.
Yeah sure. So let me clarify it was neither as it relates to O. Two two it actually was it we had very limited data and uhm I could pass it to mom it but if I believe the numbers are correct I think we had to lung cancer patients in the data set that the F. D. A saw it was relatively limited remember that was the meeting that we performed at the end of Q3 in the briefing document has to go in.
Quite a bit ahead of time, so the amount of information we actually had at 40 to 40 B I D was quite limited and so the the conversation really was to explore a new dose not specifically for one of the questions that you said efficacy and our safety, but obviously just to get more data set in general, but I think equally we had confidence in the 40 Meg Cutie.
<unk> B I D dose and so that's why we're continuing to enroll it for the for the hour program. What we tried to highlight today was for both <unk> and Red and I wasn't asked about combos, but the intention would be for us to give updates in Q1 of next year as it relates to when you should anticipate milestone updates from those program.
<unk>.
Okay.
Thank you.
Thanks, a lot Andy.
I am now turning the call back again to Athena concert you at this thank you [laughter] Ah you made me laugh by saying again, so I apologize and now I'm giggling, a little bit well. Thank you obviously, everyone for dialing in today I just want to take a moment I I. Appreciate that this is a continuing challenging year for many of you and I really.
I want to thank you for your support of US our company and close by thinking are great and growing turning point team for everything that they're doing for patients and their families and everything you've accomplished through again, a challenging year have a good evening, everyone and thank you again for Italian.
Operating me now close to call.
Thank you a few minutes.
Yes, it's been glued today's conference call. Thank you for participating you may now disconnect.
[music].
[music].
[music].
[music].